Dendreon Announces APC8024 and Provenge Presentations at American Association for Cancer Research Annual Meeting.Business Editors/Health/Medical Writers BIOWIRE2K SEATTLE--(BUSINESS WIRE)--July 8, 2003 Dendreon Corporation (Nasdaq:DNDN) today announced that its APC (1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. 8024 and Provenge(R) immunotherapies will be highlighted during the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational 94th Annual Meeting taking place July 11-14 at the Washington Convention Center The Washington Convention Center has been the name of two convention centers in Washington, D.C. The old Washington Convention Center was located at 909 H Street NW and was in use from 1983 until 2004. in Washington, D.C. Dendreon will be presenting new data on APC8024, its investigational immunotherapy for the treatment of breast, colon and ovarian cancers, which is completing Phase 1 clinical testing in patients with advanced, metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. , Her-2-positive breast cancer. Also being presented is an overview of results from the completed double blind, placebo controlled Phase 3 trial, D9901, of Provenge in patients with androgen androgen (ăn`drəjən): see testosterone. androgen Any of a group of hormones that mainly influence the development of the male reproductive system. independent prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . Presentation details are as follows:
APC8024
Saturday, July 12 Abstract #3844. Detecting Immune Responses to
1 p.m. - 5 p.m. Her-2/neu in Breast Cancer Patients Following
Poster Session Treatment with APC8024, a Therapeutic Vaccine.
Exhibit Hall B-C
Provenge
Monday, July 14 Abstract #5396. Immunotherapy (APC8015, Provenge)
Noon to 4 p.m. for Androgen Independent Prostate Cancer:
Poster Session Results from a Randomized Placebo-Controlled
Exhibit Hall B-C Trial Suggest Gleason Score Predicts Response to
Therapy
Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The company's lead investigational product candidate, Provenge, is a cancer immunotherapy Cancer immunotherapy is the use of the immune system to reject cancer. The main premise is stimulating the patient's immune system to attack the malignant tumor cells that are responsible for the disease. undergoing a pivotal Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. for the potential treatment of androgen independent prostate cancer. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing and small molecule product candidates. Dendreon has established important research and development alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd. For more information about the company and its programs, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to the uncertainty of Dendreon's future access to capital, Dendreon's limited operating history, risks associated with completing Dendreon's clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support further clinical trials or an application for a biologics license, the risk that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. will not approve a product for which a biologics license has been applied, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion